Lit Matters 1: TXA for Severe Trauma

Tranexamic acid in major trauma remains a time-sensitive hemorrhage intervention with uneven prehospital uptake across mature trauma systems. PATCH-Trauma found no improvement in favorable 6-month functional outcome, but early mortality signals still keep TXA in the conversation for severe bleeding.

TXA in Severe Trauma

• Prehospital use variability: TXA is available in many trauma systems yet used inconsistently, especially prehospital, despite longstanding concern that preventable hemorrhagic deaths occur when antifibrinolysis is delayed.
• Time-sensitive mechanism: TXA is an antifibrinolytic, and the recurring signal across trauma trials is that benefit, if present, depends on giving it early after injury rather than waiting for hospital arrival.
• PATCH-Trauma population: This trial enrolled severely injured adults with suspected trauma-induced coagulopathy using a COAST score of at least 3, with blunt trauma dominating and median Injury Severity Score reaching 29.
• Primary endpoint result: The main outcome was unequivocally negative: TXA did not improve favorable 6-month function, defined as a Glasgow Outcome Scale-Extended score of 5 or higher.
• Early mortality signal: Despite the negative primary outcome, TXA showed fewer deaths at 24 hours and 28 days by about 4 fewer per 100 treated, a tension we unpack in the episode.
• Functional tradeoff concern: The uncomfortable interpretation is that TXA may shift some patients from death to survival with severe disability, a key nuance when counseling teams about what “benefit” really means.